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Atherosclerotic vascular lesions are considered to be the
predominant cause of morbidity and mortality in indus-
trialized nations. Rupture of atherosclerotic plaques initi-
ates platelet activation/aggregation with subsequent
arterial thrombosis triggering myocardial infarction and
stroke. Nitric oxide (NO) and its second messenger cyclic
GMP (cGMP) comprise the central regulatory pathway
that prevents platelet activation/aggregation under physi-
ological conditions is. A major downstream target of NO
is cyclic guanosine 3',5'-monophosphate kinase I (cGKI).
In previous work, we have tested the intravascular signifi-
cance of the NO/cGKI signalling pathway in vivo using
cGKI-deficient (cGKI-/-) mice. We show that platelet cGKI
but not endothelial or smooth muscle cGKI is essential to
prevent intravascular adhesion and aggregation of plate-
lets after ischemia. Correspondingly, loss of cGKI in plate-
lets was associated with an increase in platelet
accumulation in the postischemic kidney and with a sig-
nificant enhancement of both platelet adhesion and
aggregation in the postischemic intestinal microvascula-
ture. The defect in platelet cGKI is not compensated by the
cAMP/cAMP kinase pathway supporting the essential role
of cGKI in prevention of ischemia-induced platelet adhe-
sion and aggregation. Next, we addressed the regulatory
cascade downstream of cGKI. We found that the inositol-
1,4,5-trisphosphate receptor-associated cGMP kinase sub-
strate (IRAG) is abundantly expressed in platelets and
assembled in a macrocomplex together with cGKI and the
inositol-1,4,5-trisphosphate receptor type I (InsP3RI).
cGKI phosphorylates IRAG at Ser664 and Ser677 in intact
platelets. Targeted deletion of the IRAG-InsP3RI interac-
tion in IRAGDelta12/Delta12 mutant mice leads to a loss
of NO/cGMP-dependent inhibition of fibrinogen-recep-
tor activation and platelet aggregation. Intracellular cal-
cium transients were not affected by DEA/NO or cGMP in
mutant platelets. Furthermore, intravital microscopy
shows that NO fails to prevent arterial thrombosis of the
injured carotid artery in IRAGDelta12/Delta12 mutants.
These findings reveal that NO/cGMP-dependent inhibi-
tion of platelet aggregation involves both cGKI and the
interaction between IRAG and InsP3RI. Modulation of
cGKI-dependent signaling might therefore provide a pow-
erful strategy to prevent arterial thrombus formation in
patients with advanced atherosclerotic vascular lesions.
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